African-American women in the Study of Women's Health Across the Nation (SWAN) experienced menopausal vasomotor symptoms for a median 10.1 years, the longest of any racial or ethnic group tracked, compared with a 7.4-year median total duration across all groups in the cohort. Symptoms persisted a median 4.5 years after the final menstrual period, and more than half of women experienced frequent vasomotor symptoms for more than 7 years across the menopausal transition (Avis et al., JAMA Internal Medicine 2015; PMID 25686030).
Halle Berry's ReSpin is a current consumer-facing entry point into the conversation about midlife health for Black women. The peer-reviewed evidence underneath that conversation runs through SWAN: three years longer median vasomotor symptom duration than the overall sample, more sleep disruption when nocturnal hot flashes occur, and a framework the American Heart Association formalized in 2020 that names the menopause transition itself as a window of accelerating cardiovascular disease risk.
Three years longer symptoms is not an aesthetic concern
The Avis 2015 SWAN paper is the largest race-stratified longitudinal cohort of US midlife women. The aggregate median vasomotor symptom duration across the full sample was 7.4 years; the African-American subgroup median was 10.1 years (median post-FMP persistence 4.5 years, PMID 25686030). That is a roughly three-year additional symptomatic window for Black women relative to the cohort average, sustained over a decade. The clinical implications carry into hormone therapy decisions and the cardiovascular conversation that follows.
Vasomotor symptoms are not an aesthetic complaint. They are the documented biological signature of the hormonal transition that the American Heart Association identified in 2020 as a CVD-acceleration window. The clinical implication is that the conversation about hormone therapy eligibility, blood pressure management, lipid panels, and weight change has a longer runway for Black women than the population-average framing implies.
The sleep evidence is specific
A 2015 actigraphy study of 314 midlife women (118 African-American, 141 white, 55 Chinese) found that nocturnal vasomotor symptoms produced more sleep-related movement, sleep fragmentation, reduced sleep efficiency, and a greater likelihood of feeling unrested upon waking (Kravitz et al., Menopause 2015; PMID 25706182). Pain severity correlated with reduced sleep efficiency in the same cohort. The actigraphy methodology means the findings rest on objective movement data, not patient self-report.
For a Black woman with frequent nocturnal hot flashes, the Kravitz finding is the evidentiary basis for treating sleep disruption as a downstream menopause-attributable health problem rather than as a separate complaint. A clinician who treats the sleep complaint without asking about menopause timing is treating a symptom in isolation from its known driver.
The AHA's 2020 framework: the menopause transition is a CVD acceleration window
In November 2020, the American Heart Association issued a Scientific Statement formalizing the menopause transition as a critical window for CVD prevention rather than a routine reproductive milestone (El Khoudary et al., Circulation 2020; PMID 33251828). The statement, authored by ten US cardiovascular researchers including Dr. JoAnn E. Manson of Brigham and Women's Hospital and Harvard Medical School, synthesized evidence on adverse changes in sex hormones, body composition, lipids, and vascular health during the transition; it framed the period as a time of accelerating CVD risk rather than a stable plateau.
The Scientific Statement does not assign a specific hazard ratio to early menopause as a discrete CV risk; it organizes the underlying evidence as a multi-mechanism case for treating midlife as a clinical-prevention inflection. For Black women whose vasomotor symptoms last longer, whose CVD baseline burden is higher, and whose hormone therapy uptake has historically been lower, the framework operationalizes as: ask about CVD risk assessment in midlife, document the menopause timeline in the chart, and treat the menopause window as a window for cardiovascular conversation, not a deferral of it.
Three named clinical voices on menopause
Dr. Stephanie S. Faubion, MD, MBA, is the Medical Director of The Menopause Society (formerly NAMS), the US professional society that publishes the standing clinical guidance on hormone therapy timing and indications. Her institutional role is the standing reference point for current Menopause Society positions in the popular press.
Dr. JoAnn E. Manson, MD, DrPH, an endocrinologist and epidemiologist at Brigham and Women's Hospital and Harvard Medical School, was a senior author on the 2020 AHA Scientific Statement and has published extensively on menopause hormone therapy and CVD risk over the last two decades.
Dr. Jessica Shepherd, MD, MBA, a board-certified obstetrician-gynecologist who founded a clinical practice focused on midlife women's health, is named in our editorial sourcing as a clinical voice on midlife health for Black women. Her current institutional affiliation is verified through her practice rather than an academic appointment.
The pattern across the three: clinical authority on midlife women's health is not concentrated at any single institution, and the editorial move is to name multiple credible voices rather than fold the conversation into one figure.
What the evidence does not yet tell us
Two things the peer-reviewed record does not pin down precisely. First, the specific magnitude of any early-natural-menopause CV risk for Black women is not in the AHA Scientific Statement abstract; the statement makes a qualitative case rather than reporting a specific Black-stratified hazard ratio for early menopause. Second, the SWAN reports document the longer Black-women symptom duration but do not establish the specific hormone-therapy uptake rate that would close the symptom-treatment gap. The qualitative finding that Black women's hormone therapy uptake has historically been lower than white women's is well-documented; the precise current-year percentage requires a primary-source pull before publication.
A reader who wants a definitive "how much earlier" or "how much higher CV risk" number is looking for a number the peer-reviewed record does not currently report at that precision. The right consumer move is to take the qualitative finding into the clinic conversation and let the clinician work from there.
What you can do this week
Three concrete actions for a Black woman in her early 40s or older.
First, document your menopause timeline. Date of last period, frequency and duration of hot flashes and night sweats over the last twelve months, sleep disruption frequency, mood or anxiety changes since the symptoms started. The Avis 2015 SWAN data shows that the median Black woman has a 10-year symptom window; tracking it gives the clinician something specific to work with rather than an aggregate population framing.
Second, ask your clinician for a midlife cardiovascular risk assessment that names menopause as a context. Blood pressure, lipid panel, fasting glucose, ASCVD risk score, family history. The El Khoudary 2020 AHA Scientific Statement is the citation that supports asking the question this way; it is the document that names the menopause transition as a CVD acceleration window. Our piece on ACE inhibitors versus ARBs in Black patients covers one specific BP-medication decision a midlife clinician might raise.
Third, ask whether you are a candidate for menopause hormone therapy. Current Menopause Society guidance favors hormone therapy for symptomatic women under 60 or within 10 years of final menstrual period when no contraindications apply; the historical lower uptake among Black women relative to white women is not a clinical reason to default away from the question. The Black Health provider directory lists OB-GYNs and internal medicine clinicians with verified licenses who can run that conversation; our piece on finding a Black OB-GYN covers the directory search workflow in more detail.
Citations
Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. PMID 25686030.
Kravitz HM, Zheng H, Bromberger JT, Buysse DJ, Owens J, Hall MH. An actigraphy study of sleep and pain in midlife women: the Study of Women's Health Across the Nation Sleep Study. Menopause. 2015;22(7):710-718. PMID 25706182.
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532. PMID 33251828.
Malik Johnson is a senior staff writer covering Black health. Send tips to malik@blackhealth.org.
